Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA HF
Inzucchi SE, Docherty KF, Køber L, et al.
Diabetes Care. 2021;44(2):586-594
Leggi
Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: beyond glycated haemoglobin
Helliwell R, Warnes H, Kietsiriroje N, et al.
Diabet Med. 2021 Jan 27; e14529
Leggi
A validated prediction model for end-stage kidney disease in type 1 diabetes
Vistisen D, Andersen GS, Hulman A, et al.
Diabetes Care. 2021 Jan; dc202586
Leggi
Continuous glucose monitoring: a review of the evidence in type 1 and 2 diabetes mellitus
Lin R, Brown F, James S, et al.
Diabet Med. 2021 Jan 26; e14528
Leggi
ANNALI AMD – Profili assistenziali nei soggetti con DM1 e DM2 in relazione al rischio cardiovascolare
Leggi
Effect of high-density lipoprotein cholesterol levels on overall survival and major adverse cardiovascular and cerebrovascular events
Kaur M, Ahuja KR, Khubber S, et al.
The American Journal of Cardiology. Pub. online 30 January 2021
Leggi
Risk of blindness among patients with diabetes and newly diagnosed diabetic retinopathy
Wykoff CC, Khurana RN, Nguyen QD, et al.
Diabetes Care. 2021 Jan;dc200413
Leggi
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
Mingrone G, Panunzi S, De Gaetano A, et al.
Lancet. 2021;397(10271):293-304
Leggi
Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the international diabetes closed-loop trial
Isganaitis E, Raghinaru D, Ambler-Osborn L, et al.
Diabetes Technol Ther. Pub online 21 January 2021
Leggi